The presentation of recombinant peptide libraries linked to their coding sequence can be referred to as 'peptide display'. Phage display is the most widely practiced peptide display technology but more recent alternatives such as CIS display, ribosome display and mRNA display offer advantages over phage for speed, library size and the display of unnatural amino acids. These have provided researchers with tools to address some of the failings of peptides such as their low affinity, low stability and inability to cross biological membranes. In this review, we assess some of the recent advances in peptide display and its application.
INTRODUCTION
The first and most widespread display procedure is 'phage display' where a foreign peptide is displayed on the coat of a filamentous phage and specifically recovered following a binding, or 'panning', process [1] . The underlying principle of this and other systems is the linkage of the phenotype (the individual peptide) to its genotype (the coding sequence) that enables the isolation of binding clones from extremely large populations. This selection process in which libraries containing hundreds of millions to trillions of mutations can be rapidly created, displayed and the best candidates selected in vitro is akin to Darwinian evolution and often known as 'molecular evolution' [2] [3] [4] . Phage display and other recombinant biological library systems dwarf the capacity of high-throughput screening (HTS) techniques and, as a consequence, thousands of examples have been published that describe their applications for peptides and proteins [1, [5] [6] [7] [8] .
Here, we will mainly focus our attention on the selection of peptides ($50 amino acids or less) with brief reference to larger protein examples where necessary.
DISPLAY SYSTEMS
The display systems reviewed in this article are those where the peptide library is displayed outside of the cell wall or membrane so that it is free to bind molecules in vitro. For this purpose, systems related to the yeast two hybrid and others are not included [9, 10] . The in vitro display systems can be separated into those technologies that require the peptide libraries to be cloned and expressed from cells and those that are truly in vitro in that expression and display is achieved without the need for transformation.
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Cellular approaches
Cellular approaches require cells to be transformed with a DNA library so that the encoded peptides are expressed and displayed either on the cell surface or on bacteriophage particles. Each cell or phage usually contains a single clone which is amplified by in vivo replication following selection. Cycles of binding, washing and enrichment, prior to screening, allow the interrogation of massive libraries ($10 10 members) [1] .
Phage display
Phages are viruses that infect bacterial cells, of which the rod-shaped filamentous phage have been most widely used for engineering. All phage coat proteins have been adapted to display foreign peptide and protein fusions, thereby demonstrating the versatility and the adaptability of the virus [1] . However, the major coat protein p8, by the nature of its abundance on the phage coat (2700 copies), offers advantages in displaying multiple copies of small peptides. Engineering p8 can impair the formation of a functional coat, which may be resolved by mutating p8 or expressing a mixture of both wild-type and recombinant p8 proteins using phagemid vectors. In contrast, p3, which is at the tip of the phage and is essential for infection, has been shown to be more amenable to the display of larger protein fusions [1, [11] [12] [13] .
In phage library selections, the panning procedure applies specific pressure to select a sub-population of peptides from the library that bind a target molecule, which is usually immobilized or captured onto a surface. Diversity is important as the majority of the population is lost from the system under stringent washing conditions, leaving bound peptides and their associated phage particles to be enriched by infection and re-growth in bacteria (Figure 1 ). Panning conditions are important for the selection of the best clones and ideally need to be balanced so that stringency is sufficiently high enough to isolate high affinity peptides without diminishing the yield [1, 6, [14] [15] [16] .
Short peptides of random sequence are the simplest combinatorial peptide libraries [1] . These have successfully produced hits for diverse applications from therapeutics to nanomaterials [17] . Peptides and proteins that have been selected by phage display to agonize or antagonize protein interactions are now at market or the later stages of development [5, 7, 18, 19] . One particular example is Hematide TM (peginesatide) discovered by Affymax, which acts as an agonist of the erythropoietin receptor that stimulates erythropoiesis. The peptide has been PEGylated to improve its in vivo half life and can correct anemia in patients with pure red-cell aplasia caused by antierythropoietin antibodies [20] .
Phage display has been used to select for tissuespecific peptides by in vivo panning ('biopanning') in animal and human subjects. One example of such 'biopanning' approaches has led to the discovery of a tripeptide D-(LPR) that inhibited neovascularization in a mouse angiogenesis model [8, 21, 22] . Phage 'biopanning' experiments have also shown success for delivery across tissues such as the skin and the blood brain barrier, through the gut wall and into cells [23] [24] [25] [26] . However, despite such successes, most unmodified peptides are normally rapidly degraded in vivo by proteases.
Peptides are natural substrates for proteases that are present in bodily fluids and increased resistance is required in order to improve their therapeutic potential. Folded peptides are inherently more stable and these structures range from simple loops that are maintained by a disulphide bond to more complicated topologies, folded around multiple disulphide bridges, such as cysteine knot miniproteins [1, 27, 28] . In a novel application, a chemical approach, previously used to generate synthetic structures with multiple peptide loops [29] , has been applied to peptide libraries produced by phage display. These p3 libraries contained three reactive cysteines interspaced by random residues which, when chemically treated with tris-(bromomethyl)benzene following expression, generated peptide conjugates with two loops anchored to a mesitylene core. Low nanomolar peptide inhibitors towards the protease human plasma kallikrein were subsequently isolated using this method [30] .
Phage display has revolutionized the ability to engineer larger protein biologics, in particular antibodies [6, 19, [31] [32] [33] [34] , and has also contributed greatly to the understanding and use of DNA binding proteins [35, 36] . However, not all foreign proteins are amenable to display and the expression of larger proteins and cytoplasmic proteins has been less successful due to folding and secretion problems [12, 37, 38] . Recently T7 lytic phage systems have been developed that bypass host cell synthesis and secretion mechanisms, resulting in less sequence bias in the displayed protein library [39] .
Yeast and bacterial display
Yeast cell display is an alternative method to phage display. It has advantages over phage for the presentation of mammalian proteins since it possesses eukaryotic machinery to express, assemble and export onto the surface both monomeric and oligomeric proteins in a fully native-like state [40] . In a direct comparison with phage display using the same antibody library and target, the yeast system sampled the library repertoire more comprehensively [41] . Foreign peptides and proteins (including growth factors, antibody fragments, cell-surface receptors) are usually fused to the Aga2p agglutinin subunit on the surface of the yeast cell [40] . Bacterial display is a technically related method where peptides or proteins can be expressed on the surface of Grampositive or Gram-negative cells in fusion with outer membrane proteins or on bacterial flagella [42] [43] [44] . Both yeast and bacteria systems can be used as affinity ligands for the selection of epitopes and used in conjunction with cell sorting methods [43] . The potential drawbacks of these systems are similar to phage display in that the expression of extracellular proteins is favoured and affinity maturation is complicated by avidity effects due to the multiplicity of the displayed peptides or proteins on the cell surface. Despite this, maturation of peptides and proteins has been achieved [40, 45] .
Acellular approaches
The versatility and flexibility of phage display has contributed to its adoption in many laboratories. However, it has its limitations, particularly in terms of rapidity of library generation, library size, expressed protein size and the intractability of some targets. This has prompted the development of new methods that use the same panning process but exploit the cellular machinery in a cell-free environment. Transformation, the process which is necessary to deliver the library DNA into cells, is inefficient and sets a practical threshold of $10 10 members, although phage libraries in the order of 10 12 have been reported [18] . Acellular, in vitro molecular display technologies which avoid the need for transformation enable more of the sequence landscape to be displayed, leading ultimately to greater diversity and an increased probability of higher affinity hits [46] . In addition, on-going evolution through error-prone amplification or shuffling techniques can further expand the diversity of the population [47] .
These acellular, in vitro systems use the transcription and translation machinery extracted from prokaryotic or eukaryotic cell lysates, thereby enabling theoretical library sizes up to 10 14 to be investigated. Also, they do not rely on secretory pathways for display (and therefore have less bias), can select for a wider variety of antimicrobial peptides and have less non-specific interactions. The distinguishing features of these and cellular technologies are shown in Figure 2 .
Ribosome display
The first cell-free, in vitro molecular display technique, ribosome display, was originally developed in an Escherichia coli lysate for the display of peptides. Polysomes were stalled on the mRNA template and the nascent peptide remained in a complex with the ribosomes, which could then be disrupted by EDTA. The released RNA was subsequently amplified by an RT-PCR step. Later, antibody fragments were successfully displayed on ribosomes using both bacterial and eukaryotic systems [48] [49] [50] [51] [52] . The absence of a stop codon, which stalls the ribosomes, and a C-terminal peptide spacer that facilitates correct folding of the displayed polypeptide free from steric hindrance by the ribosomal tunnel, are essential features of the technology. However, the system is sensitive to RNAse activity. Mechanisms have been employed to reduce this effect, including the use of a cell-free system of purified transcription and translation components (PUREsystem [53, 54] ), which improved the recovery of mRNA in the selection of an anti-IL-13 scFv 395-fold. This improvement was believed to be due to the lack of nucleases in the reconstituted transcription and translation mixture and the more efficient use of energy [55] . Despite the sensitivity of the RNA template to nucleases, an improved anti-fluorescein scFv was isolated from a 10 day incubation at 4 C in the presence of a competitor [56] . Ribosome display methods have been used in the selection of high affinity peptides, scFv antibody fragments and scaffolds such as ankyrin domains [14, [57] [58] [59] [60] [61] [62] .
mRNA display A related technique, mRNA (or in vitro virus) display differentiates itself from ribosome display by the formation of a covalent link between the template and the expressed protein via puromycin. Puromycin is carried on a DNA primer appended to the mRNA template and mimics amino-acyl tRNA, binding covalently to the nascent peptide as a result of the peptidyl transferase activity of the ribosome [63, 64] . The DNA primer is then used in a reverse transcription step to stabilize the RNA template in an RNA/ DNA hybrid. Coupling efficiency between protein and mRNA has been reported to be 10-40% [65] [66] [67] . mRNA display has been used for a number of different applications including the incorporation of unnatural amino acids (see below) and in the probing of tissue specific mRNA libraries for peptides that bound Bcl-X L [66, 68, 69] . In one example of its use, a random region of 80 amino acids was used to select an 109-mer ATP binding protein with an affinity of 100 nM following 18 rounds of selection [70] . A similar system containing a biotinylated puromycin-linker DNA demonstrated 5-20% labelling efficiency but $0.2% yield following purification of the cDNA-protein fusion requiring up to 12 rounds of selection to give binders to IL-6 receptor [71] .
CIS and CAD display DNA-based systems have advantages of speed and stability over RNA templates as the DNA template is less sensitive to degradation. Libraries can be quickly generated by standard PCR procedures and outputs rapidly analysed by next-generation sequencing. One system, CIS display, harnesses the ability of a bacterial replication initiator protein, RepA, which exclusively binds back to its encoding DNA (termed cis-activity). This activity is dependant upon two non-coding regions 3 0 to the repA sequence that are essential for cis-activity. These regions are termed CIS and ori. The CIS element is believed to be involved in tethering and loading of the protein in cis whereas ori contains the binding region for RepA. The mechanism is unknown but it is believed that the RNA polymerase is stalled during transcription at the CIS element which allows the nascent RepA protein, which has been translated concurrently, to non-covalently attach to its binding site in the ori region of its own template. The tethering of RepA to its own DNA is strongly favoured over binding to other DNA templates (Figure 3) .
CIS display was the first published example of recovery of a specific binder from a pool of nonbinding members present at a ratio of 1 in 10 10 , therefore demonstrating potential for unprecedented library sizes [72] . The technique has been used commercially (by Isogenica Ltd., UK), for the selection of high affinity peptides and folded protein domains, including antibody fragments ( [73] and unpublished). For peptides, the technique has been adapted to select for L-peptides that have greater stability by subjecting the libraries to proteolysis and isolating peptides that were resistant to degradation. Interestingly, these peptides had increased half life in vivo thus demonstrating a wider spectrum of resistance [74] . In another adaptation of the technique, peptides were isolated that transported the RepA-DNA complex into red blood cells. When chemically synthesized and labelled with a fluorophore, a number of these peptides could be visualized within Jurkat and CHO cells [75] .
Another system, covalent antibody display (CAD), uses a cis-acting DNA binding protein (bacteriophage endonuclease P2A) that covalently links to its own coding strand through the activity of a catalytic tyrosine within its sequence. This system has been used to select for tetanus toxin binders from an immune human library with enrichment rates between 14-and 300-fold [76] .
In vitro compartmentalization
In vitro compartmentalization (IVC) mimics the natural compartments of living organisms by entrapping DNA and in vitro transcription translation (ITT) components in water-in-oil emulsions. By precisely mixing mineral containing surfactants in water, one gene is trapped in a droplet; 1 ml of emulsion contains $2 Â 10 11 droplets [77] . The method is particularly advantageous for the direct selection of the product formed through enzyme activity which is difficult using other display technologies [78] . This was initially shown for HaeIII methyltransferase (M.HaeIII) and has since led to the encapsulation in emulsions of protein libraries displayed on microbeads followed by sorting using microfluidics [77, 79, 80] . This method has been adapted in 'covalent DNA display' to exploit the capacity of M.HaeIII to covalently link with DNA, thereby establishing a genotype-phenotype link that survives the dissolution of the emulsion and can be used for selection purposes exemplified by the maturation of a phage selected SH3 domain for binding to mouse serum albumin. Efficiencies in the system are reduced by more than one DNA molecule existing per droplet or by fusion of the compartments [81] . A similar technique, known as STABLE, utilizes capture of the biotinylated genotype by the encoded library-streptavidin fusion with an efficiency of $1% [82] .
ADAPTION OF DISPLAY TECHNOLOGIES FOR UNNATURAL AMINO ACIDS
As previously mentioned, a barrier to the use of peptides in vivo is their instability. One solution is to use unnatural amino acids that are resistant to enzymatic digestion. Examples of peptides containing such additions (for example, N -methylated amino acids, hydroxyl acids and D-amino acids) occur naturally and are synthesized using a series of modular enzymes known as nonribosomal peptide synthetases (NRPSs). Libraries have been created using this approach but it remains a non-trivial task and has limited application at present. A more amenable technique has been to reprogram the genetic code for the incorporation of unnatural amino acids in order to increase the chemical repertoire of the code [83] [84] [85] .
Unnatural amino acids have been successfully used in phage display, but growth conditions of engineered E. coli strains, encoding orthogonal tRNA/ aminoacyl-tRNA synthetase (aaRS) pairs, required optimization to reduce the bias for incorporation and selection of natural residues [86, 87] . However, an alternative technique known as 'mirror image phage display' allows the conversion of natural L-amino acid based peptides into more stable unnatural D-peptides. The concept of the mirror image technique is that a D-enantiomer version of a natural target is used as bait to derive binders from L-peptide libraries that can be rapidly converted to their more stable D-forms, which retain activity against the natural L-target [88] . These peptides have greater in vivo stability, are considered to be less immunogenic and more orally available. The most notable example of this procedure is the development of subnanomolar trimeric D-peptide inhibitors of HIV fusion that were isolated from an 8-mer peptide loop library [89, 90] . For those technologies that operate acellularly, it is possible to consider engineering components of the translation system, particularly the ribosome, the tRNAs or the aaRSs to incorporate unnatural amino acids. The genetic code has three stop triplet signals which can be suppressed in natural cellular systems to encode amino acids and likewise, their function can also be adapted in recombinant systems to incorporate unusual additions [86, 87] . Biocytin, a biotin derivative of lysine, has been incorporated using mRNA display [68, 84] . However, the number of available stop codons for reassignment and the poor incorporation efficiency caused by competition with release factors limit the repertoire [83, 91] . An alternative method of expanding the code is to develop quadruplet codons offering the possibility of 264 codons, rather than 64, recognized by tRNAs possessing a four base anticodon [92] or an orthogonal ribosome that specifically recognizes a quadruplet code [93] .
Another approach to reprogramming the genetic code in vitro has been to 'pre-charge' specific tRNAs with non-proteinogenic amino acids. This may be performed chemically or biologically with enzymes that acylate tRNAs with unnatural amino acids. The Flexizyme system (PeptiDream Inc., Japan) has been developed to replace aaRSs with ribozymes that are able to synthesize a wide variety of amino acids-tRNAs that contain unnatural amino acids and is amenable to use with the purified transcription and translation components [57, 83, 94, 95] .
CONCLUSIONS
Application of display technologies to address particular weaknesses of peptides, such as their inherent lack of stability and of in vivo efficacy, has helped to reawaken interest in these polymers as credible alternatives to small molecules and other biologicals as drugs. Peptides naturally modulate biological pathways and their small size, ease of production and potential lack of immunogenicity make them strong candidates for therapeutic development. The display methods permit the de novo discovery of highly active, high affinity peptides from naïve libraries; improvement of the performance of natural peptide sequences and, more increasingly, modification of binding properties of natural peptide structures. These natural peptide folds can be sampled through semi-rational engineering or such structures can be mined from genomic libraries. For example, random sampling and expression of peptides encoded by genomic DNA fragments from Archaebacteria suggest the evolution in nature of a limited repertoire of promiscuous structures that can modulate protein-protein interactions in Eukaryotes [96] .
Furthermore, in vitro display technologies allow the exploration of chemical and structural space which can be expanded through the use of unnatural side chain substitutions to potentially restrain the flexibility in peptide structures [97] . This does not exclude further optimizations through synthetic chemistry and rational design that may be complementary to such recombinant methods. Derivatization may also extend in vivo half life using formulation technologies such as PEGylation, fusion to antibody Fc fragments and albumin binding peptide motifs and provide robust candidates for therapeutic programs [98] .
Many of these technologies are still in their infancy and further improvements to the methodologies, target presentation and further panning of libraries against cells, tissues and difficult receptor targets will expand the list of targets that have so far been intractable to therapeutic intervention with biologics. The combination of these display methodologies with next-generation sequencing platforms [99] and mining of protein-protein interactions in the proteome will also facilitate the understanding of functional proteomics, the validation of therapeutic targets and disease mechanisms [100] .
Key Points
Recombinant library systems allow for greater interrogation of the natural chemical space for peptides. Larger libraries correlate with hits possessing greater affinity/activity. Phage methods are still the most adopted but other systems are demonstrating improved performance and less bias in the displayed libraries.
Selections in complex environments, i.e. in vivo, have produced encouraging results for delivery and targeting. Unnatural amino acid incorporation is possible to expand the chemical diversity of the libraries. Many peptide structures are amenable to display in these systems and will provide a future pipeline of different peptide-based biological drugs.
